

A Convenient and Efficient Synthesis of 3-benzofuryl-substituted phthalides

Yongjun Zang,^a Qilin Xu,^a Guosi Li,^a Shaoshuai Bi,^a YunFeng Ma,^{b*} and Fucheng Zhu^{a*}

^aTraditional Chinese Medicine Institute of Anhui Dabie Mountain, Department of Biological and Pharmaceutical Engineering, West Anhui University, Lu'an, Anhui 237012, P.R. China.

^bAnhui Anlito Biological Technology Co., LTD, Anhui Huoshan Economic and Technological Development Zone 237200, P.R. China

E-mail: 1973636151@qq.com, fucheng323@163.com


Received 11-29-2023

Accepted Manuscript 01-17-2024

Published on line 02-07-2024

Abstract

A highly efficient and convenient procedure for straightforward synthesizing structurally diverse 3-benzofuryl-substituted phthalides is developed with moderate to excellent yields via cyclization reactions of benzofurans with 2-carbonyl-benzoic acid. The reaction features readily available starting materials, a broad scope, and a high atom economy. Besides, an interesting regioselective was observed in some cases.



- available starting materials
- high efficiency

- 21 examples
- broad substrate scope

- up to 92% yield
- regioselective

Keywords: Phthalide, benzofuran, cyclization, heterocyclic

Introduction

The privileged heterocyclic phthalide scaffolds are widely available in natural products and pharmaceuticals.¹⁻³ Among various phthalides, 3-substituted phthalides have been proven to possess various biological activities.^{2, 4-10} Representative examples include *n*-butylphthalide, which has been approved as an anti-ischemic stroke drug in China.⁶ (±)-Catalpalactone exhibits specific cytotoxic and antiseptic activities.^{11, 12} Vermistatin displays cytotoxic effects against cancer cells.¹³ Plant growth inhibitors are displayed by (±)-Chrycolide which is obtained from the *Chrysanthemum coronarium*.¹⁴ Isopestacin shows antifungal and antioxidant activities and is isolated from the endophytic fungus *Pestalotiopsis microspore*.^{15, 16} Fluorescein is currently used as a diagnostic aid in clinical (Figure 1).¹⁷





Figure 1. Examples of biologically active 3-substituted phthalides.

As such, the construction of 3-substituted phthalides has attracted significant interest over the years.^{18, 19} Despite that a variety of synthetic approaches have been developed, the majority of these protocols generally suffer from the requirement of excess amounts of substrates, harsh conditions, and/or use of expensive or toxic transition-metal catalysts.^{5, 20} Of the various strategies, Friedel–Crafts/ lactonization of 2-formylbenzoates and nucleophiles is probably the most easily conceivable mode for formation of 3-substituted phthalides.²¹⁻²⁵

On the other hand, the benzofuran core is associated with many commercially available drugs including Dronedarone, Amiodarone, Benzbromarone, Methoxsalen, Fruquintinib.^{26, 27} Due to the wide range of biological profiles of benzofurans and 3-substituted phthalides, compounds containing the benzofuran and phthalide moieties can exhibit potential biological activities.

However, the synthesis of these both containing compounds has been scarcely studied, most notably those bearing an 3-benzofuryl-substituted phthalides. Consequently, the development of efficient and straightforward methodologies for the construction of 3-benzofuryl-substituted phthalides are greatly needed. we predicted that benzofurans might serve as potential nucleophiles suitable for use in the Friedel–Crafts/lactonization with phthalaldehydic acid for construction new benzofuran and phthalide-containing biheterocycles. Herein, we present a practical and efficient broad substrate-scope approach for the synthesis

3-benzofuryl-substituted phthalides, with moderate to excellent yields (Scheme 1). Importantly, 2-ketobenzoic acid can be performed to generate, and proceeds with high regioselectivity in our approach.



Scheme 1. The synthesis of 3-benzofuryl-substituted phthalides.


Results and Discussion

Our investigation started with using 2-ethyl-1-benzofuran (**1a**, 1.0 equiv) and 2-formylbenzoic acid (**2a**, 1.0 equiv) as the model substrates. The experiment was first performed without a mediator in dichloroethane (DCE), while none of the desired product was obtained even at reflux temperature. Employing AlCl₃ as the mediator, the reaction can be performed even at room temperature using dichloromethane (DCM) as a solvent, furnishing the corresponding product **3a** in 68% yields, establishing the necessity of the metal salt.

Encouraged by this result, we further examined the reactivity with different Lewis acids (entries **3–8**). To our delight, FeCl₃ was found as the most efficient mediator, yielding **3a** with 82% yield. Further screening of the solvents indicated DCM was the best choice. Other solvents such as toluene, THF, and 1,4-dioxane were less efficient and delivered the desired compound at a lower yield. When the reaction was conducted in water, there was no detection of any traces of the corresponding phthalide (entry 12).

Next, we examined the effects of different ratios of substrates on the reactivity. Increasing the 2-formylbenzoic acid loading to 1.1 equiv resulted in an increase in the yield of **3a** to 90% (entry 13). There was no change in the yield of the **3a** on increasing the amount of 2-formylbenzoic acid further (entry 14). Thereafter, we found that decreasing the concentration of the mediator led to a drop in the yield of the reaction (entry 15,16).

According to the above optimizations, it was found that 1.0 eq. of FeCl₃ and 1.1 eq. of a 2-formylbenzoic acid in DCM are best suited for the reaction, giving a 90% yield of **3a**.

Table 1. Optimization of the reaction conditions^a

Entry	Mediator (eq)	Solvent	1a/2a (molar ratio)	yield(%) ^b
1	None	DCE	1	0 ^c
2	AlCl ₃ (1.0)	DCM	1	68
3	ZnCl ₂ (1.0)	DCM	1	42
4	FeCl ₃ (1.0)	DCM	1	82
5	FeBr ₃ (1.0)	DCM	1	70
6	Fe(OTf) ₃ (1.0)	DCM	1	53
7	SnCl ₄ (1.0)	DCM	1	32
8	TiCl ₄ (1.0)	DCM	1	25
9	FeCl ₃ (1.0)	toluene	1	65
10	FeCl ₃ (1.0)	THF	1	71
11	FeCl ₃ (1.0)	1,4-dioxane	1	60
12	FeCl ₃ (1.0)	H ₂ O	1	0 ^c
13	FeCl ₃ (1.0)	DCM	1.1	90
14	FeCl ₃ (1.0)	DCM	1.2	90
15	FeCl ₃ (0.8)	DCM	1	75
16	FeCl ₃ (0.5)	DCM	1	48

^a Reaction conditions: **1a** (1.0 mmol), solvent (2 mL), room temperature, 1 h.

^b Isolated yield.


^c The reaction temperature was 70 °C.

After establishing the optimal conditions for the phthalide synthesis, we proceeded to examine the reaction scope in respect of the benzofurans. The results were illustrated in Table 2. Various 2-substituted benzofurans were examined first, and the corresponding products **3b-e** were all obtained in moderate to excellent yields. Delightedly, benzofurans **1d** and **1e** bearing the 2-phenyl-substituted were also amenable to the reaction, formed in moderate yields at reflux condition in DCE. The structure of **3e** was further confirmed by X-ray crystallographic study. For 5-chloro-2-formylbenzoic acid, its corresponding product **3f** was obtained in 90% yield, comparable to that of compound **3a**. While no product was detected when 2-acetylbenzofuran was used, suggesting that strongly electron-withdrawing groups are not suitable for this protocol.

After the successful synthesis of phthalide synthesis, it motivated us to extend the scope from the 2-formylbenzoic acid to 2-ketobenzoic acid core, which may be more challenging, and are barely reported. Therefore, a series of 2-ketobenzoic acid were investigated. Encouragingly, acetylbenzoic acid could react smoothly with 2-ethyl-1-benzofuran (**2a**) to afford the desired **3h** in excellent yields. Thereafter, various substituted 2-ketobenzoic acid bearing electron-donating or electron-withdrawing groups could also

preferentially be applied to this established method, affording the corresponding products **3i–n** in moderate to good yields, illustrating the generality of our current methodology.

Table 2. Substrate scope for 3-benzofuryl-substituted phthalides ^{a,b}



^a Reaction conditions: benzofuran **1** (1.0 mmol), phthalaldehydic acid **2** (1.1 mmol), FeCl_3 (1.0 mmol), DCM (2 mL), rt, 1 h.

^b Isolated yields are shown.


^c reflux in DCE.

At last, we explored the regioselectivity of the benzofuran in C-2 and C-3 in this protocol. To our exciting, various 2-ketobenzoic acid and different substituted benzofuran all smoothly participated in this process,

affording the desired products in good yields (**3o-3u**). It is worth noting that only 3-(2'-benzofuryl)-phthalides were afforded exclusively under the optimal conditions, and the 3-(3'-benzofuryl)-phthalides were not observed in these reactions, illustrating the high regioselectivity. We suppose ketone substrates are more regioselective than aldehyde substrates because ketones are significantly less reactive than aldehydes. In addition, the C2-position of benzofuran should be a little more reactive than the C3-position due to the oxygen atom having relatively strong electronegativity.

Further experimental research indicated that electron-rich substituted benzofurans proceed with complete C-2 regioselectivity in this transformation. Such as 5-methoxybenzofuran and 6-methoxybenzofuran could also be used as the qualified substrates (**3t** and **3u**), the products could be isolated in 80%, and 88% yield, respectively.

Table 3. Substrate scope for 2-substituted benzofurans ^{a,b}




^a Reaction conditions: benzofuran **1** (1.0 mmol), phthalaldehydic acid **2** (1.1 mmol), FeCl_3 (1.0 mmol), DCM (2 mL), rt, 1 h.


^b Isolated yields are shown.

For elucidation of the reaction mechanism, a control experiment between 2-ethyl-1-benzofuran (**1a**) and methyl 2-formylbenzoate was carried out (Scheme 2). While the corresponding product was not detected, instead, the bis(benzofuryl)phthalide was obtained in high yield (85%). Based on these results and also the literature precedents^{23, 28-31}, we proposed that product **3a** can be formed in two paths, and a plausible reaction pathway was proposed and depicted in Scheme 3. First, the Friedel–Crafts reaction of phthalaldehydic acid (**2a**) with 2-ethyl-1-benzofuran (**1a**) generates the intermediate **II** in the presence of FeCl_3 . At this time, in one way, intermediate **II** can undergo a rearomatization to yield benzyl alcohol **III**, which is followed by intramolecular cyclization to form the final product **3a** quickly. In the other way, complex **II** undergoes a cleavage of the C–O bond providing the benzylic carbocation **IV**. In addition, **III** also can be activated by HCl and undergoes an elimination to afford the carbocation **IV**. At last, the resulting carbocation reacts with the acid group to produce the product **3a**. As for bisbenzofuryl product **3v**, the benzyl alcohol

intermediate undergoes a second Friedel–Crafts reaction with another equivalent of **1a**, instead of intramolecular cyclization.



Scheme 2. Control experiment.



Scheme 3. A plausible mechanism for the formation of **3a**.

Conclusions

In conclusion, we have proposed a simple and effective procedure for straightforward construction 3-benzofuryl-substituted phthalides via cyclization reactions of benzofurans with 2-carbonyl-benzoic acid. The broad substrate scope, high regioselective, and high atom economy of this method make it an attractive alternative for the synthesis of complex biheterocycles, which may provide a promising approach for synthesis of bioactive compounds.

Experimental Section

General Information.

All the reagents and solvents were obtained via commercial sources and used without further purification. Analytical thin-layer chromatography (TLC) was performed on silica gel 60 F254 plates (Qingdao Ocean

Chemical Company, China). Column chromatography was carried out on silica gel (200-300 mesh, Qingdao Ocean Chemical Company, China). ^1H -NMR and ^{13}C -NMR spectra were recorded on Bruker 600 MHz and 151 MHz respectively. Chemical shift values are reported in ppm with reference to solvent signals, ^1H NMR (7.26 ppm) and ^{13}C NMR (77.00 ppm). Data are reported in chemical shifts, integration, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplets, dd = doublet of doublet), and coupling constants (J) in Hz. HRMS spectrometry data were collected on an electrospray ionization (ESI) produced by a AB SCIEX X500R QTOF.

The typical reaction procedures

A 10 mL dried round-bottom flask was charged with benzofurans (1 mmol, 1.0 equiv) and 2-carbonyl-benzoic acid **2** (1.1 mmol, 1.1 equiv), DCM or DCE (2 mL) was added, and the solution was stirred at room temperature or 70°C. Subsequently, ferric trichloride (FeCl_3) (1 mmol, 1 equiv) was added quickly. Upon complete addition, the reaction flask was stirred at room temperature or 70 °C for 1 h, and monitored by TLC. Then the reaction was quenched with H_2O (1 mL), and washed with 1N HCl (3 × 2 mL). The organic phase was dried over Na_2SO_4 . After evaporation of the solvents, the residue was purified by flash column chromatography (silica gel, PE–EtOAc, 10: 1 to afford the desired products **3**. The ^1H NMR and ^{13}C NMR spectra of the isolated 3-benzofuryl-substituted phthalides recorded in CDCl_3 .

Characterization data for the compounds

3-(2-ethylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3a). White solid (249.8 mg, 90%). ^1H NMR (600 MHz, CDCl_3) δ 8.05 (d, J 7.5 Hz, 1H), 7.66 (t, J 7.4 Hz, 1H), 7.62 (t, J 7.4 Hz, 1H), 7.40 (d, J 8.3 Hz, 1H), 7.33 (d, J 7.4 Hz, 1H), 7.16 (t, J 7.8 Hz, 1H), 6.95 (t, J 7.6 Hz, 1H), 6.64 (s, 1H), 6.46 (d, J 7.8 Hz, 1H), 2.91 (q, J 7.5 Hz, 2H), 1.40 (t, J 7.6 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.33, 160.42, 154.13, 148.53, 134.46, 129.70, 126.39, 126.22, 125.76, 123.95, 122.90, 122.81, 119.13, 111.10, 109.10, 75.76, 20.23, 13.21. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{14}\text{O}_3$: $[\text{M} + \text{H}]^+ = 279.1016$, found $m/z = 279.1008$.

3-(2-methylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3b). White solid (233.0 mg, 88%). ^1H NMR (600 MHz, CDCl_3) δ 8.05 (d, J 7.5 Hz, 1H), 7.66 (t, J 7.3 Hz, 1H), 7.62 (t, J 7.4 Hz, 1H), 7.39 (d, J 8.2 Hz, 1H), 7.34 (d, J 7.5 Hz, 1H), 7.16 (t, J 7.7 Hz, 1H), 6.96 (t, J 7.5 Hz, 1H), 6.62 (s, 1H), 6.48 (d, J 7.8 Hz, 1H), 2.56 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.29, 155.39, 154.10, 148.46, 134.48, 129.71, 126.38, 126.26, 125.77, 123.95, 122.94, 122.85, 118.95, 111.00, 110.10, 75.82, 12.50. HRMS (ESI) calcd for $\text{C}_{17}\text{H}_{12}\text{O}_3$: $[\text{M} + \text{H}]^+ = 265.0859$, found $m/z = 265.0850$.

3-(2-butylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3c). White solid (280.7 mg, 92%). ^1H NMR (600 MHz, CDCl_3) δ 8.05 (d, J 7.5 Hz, 1H), 7.66 (t, J 7.1 Hz, 1H), 7.62 (t, J 7.4 Hz, 1H), 7.40 (d, J 8.2 Hz, 1H), 7.32 (d, J 7.4 Hz, 1H), 7.16 (t, J 7.7 Hz, 1H), 6.94 (t, J 7.6 Hz, 1H), 6.62 (s, 1H), 6.43 (d, J 7.8 Hz, 1H), 2.89 (t, J 7.5 Hz, 1H), 1.85 – 1.75 (m, 1H), 1.50 – 1.39 (m, 1H), 0.97 (t, J 7.4 Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.33, 159.50, 154.15, 148.56, 134.46, 129.69, 126.46, 126.18, 125.75, 123.92, 122.92, 122.79, 119.08, 111.08, 109.78, 75.81, 30.66, 26.44, 22.34, 13.79. HRMS (ESI) calcd for $\text{C}_{20}\text{H}_{18}\text{O}_3$: $[\text{M} + \text{H}]^+ = 307.1329$, found $m/z = 307.1319$.

3-(2-phenylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3d). White solid (234.8 mg, 72%). ^1H NMR (600 MHz, CDCl_3) δ 8.12 – 8.06 (m, 1H), 7.92 (d, J 7.3 Hz, 2H), 7.66 – 7.63 (m, 2H), 7.57 (t, J 7.5 Hz, 2H), 7.54 – 7.48 (m, 2H), 7.37 – 7.30 (m, 1H), 7.23 (t, J 7.7 Hz, 1H), 6.94 (t, J 7.6 Hz, 1H), 6.81 (s, 1H), 6.26 (d, J 7.9 Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.33, 156.91, 154.39, 148.19, 134.47, 129.91, 129.83, 129.36, 129.12, 128.38, 126.53, 126.51, 125.87, 124.88, 123.27, 123.10, 120.10, 111.55, 110.21, 76.38. HRMS (ESI) calcd for $\text{C}_{22}\text{H}_{14}\text{O}_3$: $[\text{M} + \text{H}]^+ = 327.1016$, found $m/z = 327.1014$.

4-(3-(3-oxo-1,3-dihydroisobenzofuran-1-yl)benzofuran-2-yl)benzonitrile (3e). White solid (254.8 mg, 70%). ^1H NMR (600 MHz, CDCl_3) δ 8.14 – 8.08 (m, 1H), 8.05 (d, J 8.3 Hz, 2H), 7.84 (d, J 8.3 Hz, 2H), 7.74 – 7.64 (m, 2H), 7.54 (d, J 8.3 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.29 (t, J 7.7 Hz, 1H), 6.98 (t, J 7.6 Hz, 1H), 6.77 (s, 1H), 6.26 (d, J 7.9

Hz, 1H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.94, 154.64, 154.27, 147.57, 134.63, 133.55, 132.81, 130.14, 128.63, 126.41, 126.19, 126.09, 125.90, 123.55, 123.25, 120.54, 118.29, 113.22, 112.61, 111.78, 75.55. HRMS (ESI) calcd for $\text{C}_{23}\text{H}_{13}\text{NO}_3$: $[\text{M} + \text{H}]^+ = 352.0968$, found $m/z = 352.0966$.

6-chloro-3-(2-ethylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3f). White solid (281.4 mg, 90%). ^1H NMR (600 MHz, CDCl_3) δ 8.01 (s, 1H), 7.62 (d, J 8.1 Hz, 1H), 7.41 (d, J 8.3 Hz, 1H), 7.26 (d, J 9.0 Hz, 1H), 7.22 – 7.15 (m, 1H), 6.98 (t, J 7.5 Hz, 1H), 6.61 (s, 1H), 6.47 (d, J 7.8 Hz, 1H), 2.91 (q, J 7.6 Hz, 2H), 1.40 (t, J 7.6 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 168.80, 160.63, 154.14, 146.67, 136.07, 134.78, 128.23, 125.97, 125.69, 124.22, 124.11, 122.97, 118.97, 111.22, 108.52, 75.69, 20.23, 13.25. HRMS (ESI) calcd for $\text{C}_{18}\text{H}_{13}\text{ClO}_3$: $[\text{M} + \text{H}]^+ = 313.0631$, found $m/z = 313.0629$.

3-(2-ethylbenzofuran-3-yl)-3-methylisobenzofuran-1(3H)-one (3h). White solid (248.5 mg, 85%). ^1H NMR (600 MHz, CDCl_3) δ 7.96 (d, J 7.6 Hz, 1H), 7.63 (t, J 7.2 Hz, 1H), 7.54 (t, J 7.5 Hz, 1H), 7.51 (d, J 7.7 Hz, 1H), 7.39 (d, J 8.2 Hz, 1H), 7.32 (d, J 7.9 Hz, 1H), 7.21 (t, J 7.7 Hz, 1H), 7.14 (t, J 7.6 Hz, 1H), 2.85 – 2.74 (m, 2H), 2.21 (s, 3H), 1.23 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.76, 157.35, 154.35, 153.81, 134.49, 129.42, 127.02, 125.86, 125.08, 123.71, 122.68, 121.92, 120.47, 113.30, 111.12, 85.36, 28.00, 21.94, 13.03. HRMS (ESI) calcd for $\text{C}_{19}\text{H}_{16}\text{O}_3$: $[\text{M} + \text{H}]^+ = 293.1172$, found $m/z = 293.1167$.

3-(2-ethylbenzofuran-3-yl)-3-phenylisobenzofuran-1(3H)-one (3i). White solid (290.6 mg, 82%). ^1H NMR (600 MHz, CDCl_3) δ 7.99 (d, J 7.6 Hz, 1H), 7.67 (t, J 7.5 Hz, 1H), 7.64 – 7.56 (m, 2H), 7.51 – 7.45 (m, 2H), 7.42 – 7.32 (m, 4H), 7.16 (t, J 7.7 Hz, 1H), 6.95 (t, J 7.6 Hz, 1H), 6.52 (d, J 8.0 Hz, 1H), 2.44 – 2.29 (m, 2H), 1.09 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.68, 159.07, 153.79, 151.94, 140.21, 134.22, 129.73, 128.94, 128.81, 127.46, 126.53, 126.10, 125.50, 124.00, 123.64, 122.52, 120.87, 113.86, 110.88, 88.38, 21.48, 12.59. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{O}_3$: $[\text{M} + \text{H}]^+ = 355.1329$, found $m/z = 355.1321$.

3-(2-ethylbenzofuran-3-yl)-6-methyl-3-phenylisobenzofuran-1(3H)-one (3j). White solid (265.3 mg, 72%). ^1H NMR (600 MHz, CDCl_3) δ 7.97 (d, J 7.6 Hz, 1H), 7.65 (t, J 7.4 Hz, 1H), 7.62 – 7.55 (m, 2H), 7.38 (d, J 8.2 Hz, 1H), 7.34 (d, J 8.0 Hz, 2H), 7.16 (t, J 7.2 Hz, 3H), 6.96 (t, J 7.6 Hz, 1H), 2.44 – 2.36 (m, 2H), 2.35 (s, 3H), 1.10 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.75, 158.94, 153.78, 152.16, 138.87, 137.15, 134.17, 129.61, 129.46, 127.51, 126.51, 126.03, 125.50, 123.91, 123.58, 122.47, 120.95, 113.93, 110.84, 88.45, 21.50, 21.17, 12.62. HRMS (ESI) calcd for $\text{C}_{25}\text{H}_{20}\text{O}_3$: $[\text{M} + \text{H}]^+ = 368.1485$, found $m/z = 368.1484$.

3-(2-ethylbenzofuran-3-yl)-6-hydroxy-3-phenylisobenzofuran-1(3H)-one (3k). White solid (296.0 mg, 80%). ^1H NMR (600 MHz, CDCl_3) δ 7.97 (d, J 7.8 Hz, 1H), 7.66 (t, J 7.4 Hz, 1H), 7.61 – 7.54 (m, 2H), 7.37 (d, J 8.2 Hz, 1H), 7.24 (d, J 8.5 Hz, 2H), 7.15 (t, J 7.7 Hz, 1H), 6.96 (t, J 7.6 Hz, 1H), 6.81 (d, J 8.2 Hz, 2H), 6.63 (d, J 7.9 Hz, 1H), 2.50 – 2.36 (m, 2H), 1.09 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.46, 158.68, 156.64, 153.78, 152.26, 134.41, 129.64, 128.40, 127.35, 126.02, 125.39, 123.85, 123.65, 122.55, 120.93, 115.69, 113.91, 110.88, 89.04, 21.51, 12.67. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{O}_4$: $[\text{M} + \text{H}]^+ = 371.1278$, found $m/z = 371.1263$.

6-chloro-3-(2-ethylbenzofuran-3-yl)-3-phenylisobenzofuran-1(3H)-one (3l). White solid (326.6 mg, 84%). ^1H NMR (600 MHz, CDCl_3) δ 7.99 (d, J 7.6 Hz, 1H), 7.68 (t, J 7.5 Hz, 1H), 7.61 (t, J 7.5 Hz, 1H), 7.58 (t, J 7.9 Hz, 1H), 7.40 (t, J 8.2 Hz, 3H), 7.34 (d, J 8.5 Hz, 2H), 7.18 (t, J 7.7 Hz, 1H), 6.98 (t, J 7.6 Hz, 1H), 6.55 (d, J 7.9 Hz, 1H), 2.46 – 2.33 (m, 2H), 1.11 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.39, 159.02, 153.80, 151.53, 138.83, 135.04, 134.38, 129.94, 129.05, 128.01, 127.22, 126.25, 125.37, 123.80, 122.65, 120.76, 113.42, 110.98, 87.78, 21.56, 12.59. HRMS (ESI) calcd for $\text{C}_{24}\text{H}_{17}\text{ClO}_3$: $[\text{M} + \text{H}]^+ = 389.0939$, found $m/z = 389.0931$.

3-(3-chloro-4-nitrophenyl)-3-(2-ethylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3m). White solid (336.6 mg, 80%). ^1H NMR (600 MHz, CDCl_3) δ 8.03 (d, J 7.6 Hz, 1H), 7.94 (d, J 2.2 Hz, 1H), 7.74 (t, J 8.0 Hz, 1H), 7.70 – 7.64 (m, 2H), 7.59 (d, J 7.7 Hz, 1H), 7.57 (d, J 8.5 Hz, 1H), 7.42 (d, J 8.2 Hz, 1H), 7.21 (t, J 7.8 Hz, 1H), 7.02 (t, J 7.6 Hz, 1H), 6.52 (d, J 7.9 Hz, 1H), 2.47 – 2.36 (m, 2H), 1.13 (t, J 7.5 Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 168.69, 159.29, 153.86, 150.33, 148.07, 141.07, 134.88, 132.54, 131.18, 130.55, 127.79, 126.69, 126.67, 125.20,

124.18, 123.65, 123.48, 122.98, 120.35, 112.46, 111.28, 86.62, 21.69, 12.53. HRMS (ESI) calcd for C₂₄H₁₆ClNO₅: [M + H]⁺ = 434.0790, found *m/z* = 434.0790.

3-([1,1'-biphenyl]-4-yl)-3-(2-ethylbenzofuran-3-yl)isobenzofuran-1(3H)-one (3n). White solid (327.1mg, 76%). ¹H NMR (600 MHz, CDCl₃) δ 8.00 (d, *J* 7.6 Hz, 1H), 7.69 (t, *J* 7.4 Hz, 1H), 7.64 (d, *J* 7.6 Hz, 1H), 7.62 – 7.56 (m, 5H), 7.54 (d, *J* 8.4 Hz, 2H), 7.43 (t, *J* 7.6 Hz, 2H), 7.40 (d, *J* 8.2 Hz, 1H), 7.35 (t, *J* 7.4 Hz, 1H), 7.17 (t, *J* 7.7 Hz, 1H), 6.97 (t, *J* 7.6 Hz, 1H), 6.60 (d, *J* 7.9 Hz, 1H), 2.49 – 2.35 (m, 2H), 1.12 (t, *J* 7.5 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 169.67, 159.09, 153.81, 151.94, 141.74, 140.08, 139.10, 134.29, 129.77, 128.89, 127.74, 127.43, 127.10, 127.02, 126.15, 125.51, 123.98, 123.68, 122.57, 120.94, 113.78, 110.91, 88.29, 21.56, 12.62. HRMS (ESI) calcd for C₃₀H₂₂O₃: [M + H]⁺ = 431.1642, found *m/z* = 431.1637.

3-(benzofuran-2-yl)-3-methylisobenzofuran-1(3H)-one (3o). White solid (237.7 mg, 90%). ¹H NMR (600 MHz, CDCl₃) δ 7.95 (d, *J* 7.6 Hz, 1H), 7.70 (t, *J* 7.5 Hz, 1H), 7.58 (dd, *J* 13.6, 7.5 Hz, 2H), 7.52 (d, *J* 7.7 Hz, 1H), 7.42 (d, *J* 8.3 Hz, 1H), 7.28 (t, *J* 7.2 Hz, 1H), 7.21 (t, *J* 7.4 Hz, 1H), 6.68 (s, 1H), 2.10 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 169.35, 155.26, 154.93, 151.31, 134.47, 129.78, 127.54, 126.01, 125.44, 125.00, 123.15, 122.20, 121.43, 111.49, 104.14, 83.20, 24.92. HRMS (ESI) calcd for C₁₇H₁₂O₃: [M + H]⁺ = 265.0859, found *m/z* = 265.0861.

3-(benzofuran-2-yl)-3-phenylisobenzofuran-1(3H)-one (3p). White solid (280.6 mg, 86%). ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* 7.7 Hz, 1H), 7.78 – 7.70 (m, 2H), 7.61 (t, *J* 6.9 Hz, 1H), 7.53 (d, *J* 7.7 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.42 (d, *J* 8.3 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.29 (t, *J* 7.6 Hz, 1H), 7.22 (t, *J* 7.4 Hz, 1H), 6.74 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 169.27, 155.58, 154.49, 149.93, 137.84, 134.48, 129.98, 129.20, 128.76, 127.34, 126.57, 126.14, 125.49, 125.14, 124.04, 123.24, 121.53, 111.65, 106.65, 86.76. HRMS (ESI) calcd for C₂₂H₁₄O₃: [M + H]⁺ = 327.1021, found *m/z* = 327.1023.

3-(7-bromobenzofuran-2-yl)-3-phenylisobenzofuran-1(3H)-one (3q). White solid (348.3 mg, 86%). ¹H NMR (600 MHz, CDCl₃) δ 7.97 (d, *J* 7.7 Hz, 1H), 7.85 (d, *J* 7.8 Hz, 1H), 7.76 (t, *J* 7.9 Hz, 1H), 7.61 (t, *J* 7.4 Hz, 1H), 7.47 (d, *J* 7.7 Hz, 1H), 7.46 – 7.41 (m, 3H), 7.40 – 7.36 (m, 3H), 7.10 (t, *J* 7.8 Hz, 1H), 6.89 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 169.16, 155.35, 152.70, 149.71, 137.68, 134.66, 130.10, 129.33, 128.81, 128.66, 128.11, 126.63, 126.12, 125.32, 124.55, 124.31, 120.67, 106.54, 104.23, 86.50, 26.93. HRMS (ESI) calcd for C₂₂H₁₃BrO₃: [M + H]⁺ = 405.0121, found *m/z* = 405.1118.

3-(5-bromobenzofuran-2-yl)-3-phenylisobenzofuran-1(3H)-one (3r). White solid (328.2mg, 81%). ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* 7.7 Hz, 1H), 7.77 – 7.71 (m, 2H), 7.66 (s, 1H), 7.64 – 7.60 (m, 1H), 7.47 – 7.41 (m, 2H), 7.41 – 7.36 (m, 4H), 7.28 (d, *J* 8.8 Hz, 1H), 6.69 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 169.07, 155.95, 154.30, 149.57, 137.53, 134.59, 130.14, 129.33, 128.84, 128.12, 126.50, 126.24, 125.44, 124.17, 123.99, 116.31, 113.12, 106.00, 86.45. HRMS (ESI) calcd for C₂₂H₁₃BrO₃: [M + H]⁺ = 405.0121, found *m/z* = 405.1119.

3-(6-bromobenzofuran-2-yl)-3-phenylisobenzofuran-1(3H)-one (3s). White solid (348.1 mg, 86%). ¹H NMR (600 MHz, CDCl₃) δ 7.98 (d, *J* 7.7 Hz, 1H), 7.76 – 7.72 (m, 2H), 7.62 (t, *J* 6.8 Hz, 1H), 7.59 (s, 1H), 7.47 – 7.41 (m, 2H), 7.41 – 7.32 (m, 5H), 6.72 (s, 1H). ¹³C NMR (151 MHz, CDCl₃) δ 169.10, 155.78, 155.27, 149.62, 137.53, 134.57, 130.12, 129.33, 128.82, 126.76, 126.52, 126.39, 126.22, 125.44, 123.98, 122.46, 118.42, 115.13, 106.44, 86.49. HRMS (ESI) calcd for C₂₂H₁₃BrO₃: [M + H]⁺ = 405.0121, found *m/z* = 405.1122.

(6-methoxybenzofuran-2-yl)isobenzofuran-1(3H)-one (3t). White solid (224.4 mg, 80%). ¹H NMR (600 MHz, CDCl₃) δ 8.04 – 7.93 (m, 1H), 7.84 – 7.70 (m, 2H), 7.68 – 7.59 (m, 2H), 7.41 (d, *J* 8.6 Hz, 1H), 6.97 (s, 1H), 6.91 – 6.86 (m, 1H), 6.78 (s, 1H), 3.82 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 168.09, 158.73, 156.60, 150.86, 144.10, 112.72, 106.90, 99.06, 95.93, 82.28, 55.69. HRMS (ESI) calcd for C₁₇H₁₂O₄: [M + H]⁺ = 281.0808, found *m/z* = 281.0813.

3-(5-methoxybenzofuran-2-yl)isobenzofuran-1(3H)-one (3u). White solid (232.5 mg, 83%). ¹H NMR (600 MHz, CDCl₃) δ 7.99 (d, *J* 7.6 Hz, 1H), 7.60 (t, *J* 7.5 Hz, 1H), 7.54 (t, *J* 7.5 Hz, 1H), 7.46 (s, 1H), 7.45 (d, *J* 6.7 Hz, 1H), 7.38 (d, *J* 7.6 Hz, 1H), 7.16 (s, 1H), 7.00 (d, *J* 9.0 Hz, 1H), 6.18 (s, 1H), 3.94 (s, 3H). ¹³C NMR (151 MHz, CDCl₃) δ

171.11, 150.38, 150.30, 146.58, 134.30, 129.15, 126.16, 125.90, 125.43, 122.94, 115.88, 112.35, 109.12, 105.14, 57.12. HRMS (ESI) calcd for C₁₇H₁₂O₄: [M + H]⁺ = 281.0808, found *m/z* = 281.0810.

methyl 2-(bis(2-ethylbenzofuran-3-yl)methyl)benzoate (3v). White solid (186.4 mg, 85%). ¹H NMR (600 MHz, CDCl₃) δ 7.84 (d, *J* 7.4 Hz, 1H), 7.41 – 7.32 (m, 5H), 7.13 (t, *J* 7.7 Hz, 2H), 6.96 (t, *J* 7.3 Hz, 2H), 6.86 (d, *J* 9.0 Hz, 3H), 3.57 (s, 3H), 2.54 – 2.42 (m, 4H), 1.09 (t, *J* 7.5 Hz, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 168.18, 167.49, 156.87, 153.80, 142.34, 131.59, 130.83, 130.72, 129.73, 129.47, 126.91, 123.04, 122.20, 119.83, 114.25, 110.61, 51.97, 34.09, 20.24, 12.16. HRMS (ESI) calcd for C₂₉H₂₆O₄: [M - H]⁻ = 437.1747, found *m/z* = 437.1764.

Acknowledgements

This research was funded by the National Natural Science Foundation of China (32201979), Scientific Research Project of Anhui province (2022AH051682), West Anhui University (WGKQ2022079), Traditional Chinese Medicine Institute of Anhui Dabie Mountain (TCMADM-2023-14).

Supplementary Material

Characterization data including copies of ¹H and ¹³C NMR spectra associated with this paper and X-ray crystallography data for compound **3e** can be found in the online version.

References

1. Awasthi, A.; Singh, M.; Rathee, G.; Chandra, R. *RSC Advances* **2020**, *10*, 12626-12652.
<https://10.1039/d0ra00701c>
2. Sadıkoğulları, B. C.; Şenel, P.; Çini, N.; Faysal, A. A.; Odabaşoğlu, M.; Özdemir, A. D.; Gölcü, A. *ChemistrySelect* **2022**, *7*, e202202004.
<https://10.1002/slct.202202004>
3. Wei, X.; Zeng, Y.; Sun, C.; Meng, F.; Wang, Y. *Fitoterapia* **2022**, *160*, 105223.
<https://10.1016/j.fitote.2022.105223>
4. da Silva Maia, A. F.; Siqueira, R. P.; de Oliveira, F. M.; Ferreira, J. G.; da Silva, S. F.; Caiuby, C. A. D.; de Oliveira, L. L.; de Paula, S. O.; Souza, R. A. C.; Guilardi, S.; Bressan, G. C.; Teixeira, R. R. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 2810-2816.
<https://10.1016/j.bmcl.2016.04.065>
5. Jia, L.; Han, F. *Beilstein J. Org. Chem.* **2017**, *13*, 1425-1429.
<https://10.3762/bjoc.13.139>
6. Marco-Contelles, J.; Zhang, Y. *J. Med. Chem.* **2020**, *63*, 12485-12510.
<https://10.1021/acs.jmedchem.0c00887>
7. Ortega, M. J.; Parra-Torrejón, B.; Cano-Cano, F.; Gómez-Jaramillo, L.; González-Montelongo, M. C.; Zubía, E. *Pharmaceuticals* **2022**, *15*, 588.
<https://10.3390/ph15050588>
8. Touchet, S.; Kommidi, S. S. R.; Gros, P. C. *ChemistrySelect* **2018**, *3*, 3939-3942.
<https://10.1002/slct.201800178>

9. Wang, R.; Xu, H.; Li, T.; Zhang, Y.; Wang, S.; Chen, G.; Li, C.; Zhao, H., *ChemCatChem* **2020**, *12*, 5907-5911.
<https://10.1002/cctc.202001214>
10. Yang, J.; Yoshikai, N. *J. Am. Chem. Soc.* **2014**, *136*, 16748-16751.
<https://10.1021/ja509919x>
11. Höller, U.; Gloer, J. B.; Wicklow, D. T. *J. Nat. Prod.* **2002**, *65*, 876-882.
<https://10.1021/np020097y>
12. Jadulco, R.; Brauers, G.; Edrada, R. A.; Ebel, R.; Wray, V.; Sudarsono; Proksch, P. *J. Nat. Prod.* **2002**, *65*, 730-733.
<https://10.1021/np010390i>
13. Fuska, J.; Uhrín, D.; Proksa, B.; Votický, Z.; Ruppeltdt, J. *J. Antibiot.* **1986**, *39*, 1605-1608.
<https://10.7164/antibiotics.39.1605>
14. Tada, M.; Chiba, K. *Agri. Biol. Chem.* **1984**, *48*, 1367-1369.
<https://10.1271/bbb1961.48.1367>
15. Pahari, P.; Senapati, B.; Mal, D. *Tetrahedron Lett.* **2004**, *45*, 5109-5112.
<https://10.1016/j.tetlet.2004.04.175>
16. Strobel, G.; Ford, E.; Worapong, J.; Harper, J. K.; Arif, A. M.; Grant, D. M.; Fung, P. C. W.; Ming Wah Chau, R. *Phytochemistry* **2002**, *60*, 179-183.
[https://10.1016/s0031-9422\(02\)00062-6](https://10.1016/s0031-9422(02)00062-6)
17. Arrousse, N.; Salim, R.; Obot, I. B.; Abdellaoui, A.; El Hajjaji, F.; Mabrouk, E.; Taleb, M. *J. Mol. Liq.* **2022**, *359*, 119311.
<https://10.1016/j.molliq.2022.119311>
18. Cheng, J.; Liu, M.; Chen, Z.; Gong, T. *Chinese J. Org. Chem.* **2022**, *42*, 1085-1100.
<https://10.6023/cjoc202109006>
19. Li, Z.; Han, Y.; Bai, R.; Jiang, L.; Li, Q. *Chinese J. Org. Chem.* **2021**, *41*, 3390-3399.
<https://10.6023/cjoc202104063>
20. Fortier, L.; Gosset, C.; Lefebvre, C.; Pellegrini, S.; Péliniski, L.; Bousquet, T. *Eur. J. Org. Chem.* **2023**, *26*, e202201247.
<https://10.1002/ejoc.202201247>
21. Guo, T.; Wang, H. J.; Cao, C. C.; Chen, K. H.; Liu, Y.; Zhang, P. K.; Zhao, Y. H.; Ma, Y. C. *Eur. J. Org. Chem.* **2020**, 3613-3621.
<https://10.1002/ejoc.202000308>
22. Lin, G.; Sun, X.-W.; Shen, S.-C. *Synthesis* **2013**, *45*, 1181-1190.
<https://10.1055/s-0032-1316871>
23. Lin, H.; Sun, X.-W. *Tetrahedron Lett.* **2008**, *49*, 5343-5346.
<https://10.1016/j.tetlet.2008.06.055>
24. Mohanakrishnan, A.; Nandakumar, M.; Sankar, E. *Synlett* **2014**, *25*, 509-514.
<https://10.1055/s-0033-1340551>
25. Tian, Y.; Liu, Q.; Liu, Y.; Zhao, R.; Li, G.; Xu, F. *Tetrahedron Lett.* **2018**, *59*, 1454-1457.
<https://10.1016/j.tetlet.2018.02.083>
26. Nevagi, R. J.; Dighe, S. N.; Dighe, S. N. *Eur. J. Med. Chem.* **2015**, *97*, 561-581.
<https://10.1016/j.ejmech.2014.10.085>
27. Abbas, A. A.; Dawood, K. M. *RSC Advances* **2023**, *13*, 11096-11120.
<https://10.1039/d3ra01383a>
28. Sheryn, W.; Ninomiya, M.; Koketsu, M.; Hasbullah, S. A. *Arab. J. Chem.* **2020**, *13*, 3856-3865.

<https://10.1016/j.arabjc.2019.02.002>

29. Shi, Z.; Chen, S.; Xiao, Q.; Yin, D. *J. Org. Chem.* **2021**, *86*, 3334-3343.

<https://10.1021/acs.joc.0c02694>

30. Yang, G. P.; Dilixiati, D.; Yang, T.; Liu, D.; Yu, B.; Hu, C. W. *Appl. Organomet. Chem.* **2018**, *32*, e4450.

<https://10.1002/aoc.4450>

31. Zang, Y.; Ma, Y.; Xu, Q.; Li, G.; Chen, N.; Li, X.; Zhu, F. *Org. Biomol. Chem.* **2024**, *22*, 932-939.

<https://10.1039/d3ob01977b>

This paper is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>)